Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

Next Previous
Search
Trial Profile

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Batiraxcept (Primary) ; Doxorubicin liposomal; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Aravive; Aravive Biologics

    • Most Recent Events

    • 16 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2022 Data from NCT03639246 and NCT03401528 has been used to develop population pharmacokinetic (PK) /pharmacodynamic (PD) model presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 02 Mar 2022 According to an Aravive media release, data from Phase 1b platinum-resistant ovarian cancer will be presented at the American Association for Cancer Research (AACR) annual meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top